Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment

BACKGROUND: Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment. OBJECTIVES: To examine whole and segmented gray, white, thal...

Descripción completa

Detalles Bibliográficos
Autores principales: Koskimäki, Fredrika, Bernard, Jacqueline, Yong, Jeong, Arndt, Nancy, Carroll, Timothy, Lee, Seon-Kyu, Reder, Anthony T., Javed, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303064/
https://www.ncbi.nlm.nih.gov/pubmed/30576361
http://dx.doi.org/10.1371/journal.pone.0209326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303064/
https://www.ncbi.nlm.nih.gov/pubmed/30576361
http://dx.doi.org/10.1371/journal.pone.0209326

Ejemplares similares